~~<i id='5D002C7524'><strike id='5D002C7524'><tt id='5D002C7524'><pre id='5D002C7524'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：hotspot 2025-10-06 19:17:52 Page View：9

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Health AI: on the border between health care and tech
Next article： Heart attack and stroke risk calculators need revising

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Biden administration begins canceling student loan debt for 804,000 borrowers

9:50EducationSecretaryMiguelCardonaspeaksduringaback-to-schoolK-12CybersecuritySummitintheEastRoomof

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Private equity could exacerbate cardiology's overuse problem, experts fear

AdobeCoronarystentingis,bysomemeasures,themostoverusedprocedureinhospitals.Theproblemcoststhehealths